Fetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human Health
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 3
Abstract
Fetal microchimerism is the co-existence of small numbers of cells from genetically distinct individuals living within a mother’s body following pregnancy. During pregnancy, bi-directional exchange of cells occurs resulting in maternal microchimerism and even sibling microchimerism in offspring. The presence of fetal microchimerism has been identified with lower frequency in patients with cancers such as breast and lymphoma and with higher frequency in patients with colon cancer and autoimmune diseases. Microchimeric cells have been identified in healing and healed tissues as well as normal and tumor tissues. This has led to the hypothesis that fetal microchimerism may play a protective role in some cancers and may provoke other cancers or autoimmune disease. The long periods of risk for these diseases make it a challenge to prospectively study this phenomenon in human populations. Dogs get similar cancers as humans, share our homes and environmental exposures, and live compressed life-spans, allowing easier prospective study of disease development. This review describes the current state of understanding of fetal microchimerism in humans and dogs and highlights the similarities of the common cancers mammary carcinoma, lymphoma, and colon cancer between the two species. Study of fetal microchimerism in dogs might hold the key to characterization of the type and function of microchimeric cells and their role in health and disease. Such an understanding could then be applied to preventing and treating disease in humans.
Authors and Affiliations
Jeffrey N. Bryan
Keywords
Related Articles
- EP ID EP680939
- DOI 10.1208/s12248-015-9731-y
- Views 51
- Downloads 0
Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis
The online version of this article (doi:10.1208/s12248-014-9654-z) contains supplementary material, which is available to authorized users.
AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology
The first International Symposium of Nanomedicine on AIDS “AIDS Treatment with Novel Anti-HIV compounds Improved by Nanotechnology” was held November 19–20, 2009 in Beijing, China. This symposium...
Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry
GTI-2040 is a 20-mer phosphorothioate oligonucleotide, which is complementary to the messenger ribonucleic acid (mRNA) of the R2 subunit of ribonucleotide reductase. This study characterized both the in vivo and in vitro...
Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume
The online version of this article (doi:10.1208/s12248-016-9885-2) contains supplementary material, which is available to authorized users.
Completeness Assessment of Type II Active Pharmaceutical Ingredient Drug Master Files under Generic Drug User Fee Amendment: Review Metrics and Common Incomplete Items
Under the Generic Drug User Fee Amendments (GDUFA) of 2012, Type II active pharmaceutical ingredient (API) drug master files (DMFs) must pay a user fee and pass a Completeness Assessment (CA) before they can be reference...